◀ Back to MAPK11
DUSP16 — MAPK11
Pathways - manually collected, often from reviews:
-
KEGG MAPK signaling pathway:
DUSP1/DUSP10/DUSP14/DUSP16/DUSP2/DUSP22/DUSP3/DUSP4/DUSP5/DUSP6/DUSP7/DUSP8/DUSP9
→
MAPK11/MAPK12/MAPK13/MAPK14
(protein-protein, inhibition)
-
NCI Pathway Database Regulation of p38-alpha and p38-beta:
p38alpha-beta-active (MAPK14/MAPK11)
→
p38alpha-beta/MKP7 complex (MAPK14_MAPK11-DUSP16)
(modification, collaborate)
Tanoue et al., J Biol Chem 2001
Evidence: mutant phenotype, physical interaction
-
NCI Pathway Database Regulation of p38-alpha and p38-beta:
p38alpha-beta-active (MAPK14/MAPK11)
→
MKP7 (DUSP16)
(modification, collaborate)
Tanoue et al., J Biol Chem 2001
Evidence: mutant phenotype, physical interaction
-
NCI Pathway Database Regulation of p38-alpha and p38-beta:
p38alpha-beta/MKP7 complex (MAPK14_MAPK11-DUSP16)
→
MKP7 (DUSP16)
(modification, collaborate)
Tanoue et al., J Biol Chem 2001
Evidence: mutant phenotype, physical interaction
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Givant-Horwitz et al., Gynecol Oncol 2004
(MAP Kinase Signaling System...) :
The objective of the present study was to investigate the expression and clinical role of
dual-specificity phosphatases ( DUSP ) ,
inhibitors of
MAPK signaling, in ovarian cancer cells at this site
Kumabe et al., Microbiol Immunol 2010
:
Activation of
MAPK is negatively
regulated by
DUSP , which dephosphorylate the phosphothreonine and phosphotyrosine residues